scholarly journals Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol.

1989 ◽  
Vol 64 (4) ◽  
pp. 587-592 ◽  
Author(s):  
A A Massarano ◽  
C G Brook ◽  
P C Hindmarsh ◽  
P J Pringle ◽  
J D Teale ◽  
...  
1968 ◽  
Vol 43 (231) ◽  
pp. 595-597 ◽  
Author(s):  
S. R. Meadow ◽  
B. J. Boucher ◽  
K. Mashiter ◽  
M. N. King ◽  
L. Stimmler

Author(s):  
S. Bemasconi ◽  
L. Ghizzoni ◽  
C. Volta ◽  
M. Morano ◽  
G. Giovannelli

1990 ◽  
Vol 71 (3) ◽  
pp. 770-772 ◽  
Author(s):  
ROBERTO LANES ◽  
SARA BRITO ◽  
MARIA SUNIAGA ◽  
GUSTAVO MONCADA ◽  
MARIETTA BORGES

2007 ◽  
Vol 88 (6) ◽  
pp. 610-613 ◽  
Author(s):  
P Pirazzoli ◽  
L Mazzanti ◽  
R Bergamaschi ◽  
A Perri ◽  
E Scarano ◽  
...  

1976 ◽  
Vol 81 (1) ◽  
pp. 9-18 ◽  
Author(s):  
Paul Saenger ◽  
Ernest Schwartz ◽  
Eckehart Wiedemann ◽  
Lenore S. Levine ◽  
Mary Tsai ◽  
...  

ABSTRACT Baseline somatomedin activity in seven of eight patients with Turner's syndrome was found to be within normal limits. Somatomedin activity readily suppressed with oestrogen administration. The overall mean serum somatomedin activity during oestrogen therapy (0.87 U/ml, sd 0.15) was significantly lower (P < 0.005) than the mean of the control serum somatomedin activities (1.09 U/ml, sd 0.24). During oestrogen therapy, suggestive elevations of fasting growth hormone levels were noted in five of eight patients. The data indicate that oestrogenic suppression of serum somatomedin was not due to decreased growth hormone secretion and suggest the existence of a negative feedback link between somatomedin and growth hormone.


Metabolism ◽  
1995 ◽  
Vol 44 (8) ◽  
pp. 1033-1037 ◽  
Author(s):  
Fabrizio Vaccaro ◽  
Stefano Cianfarani ◽  
Anna Maria Pasquino ◽  
Brunetto Boscherini

1989 ◽  
Vol 120 (3_Suppl) ◽  
pp. S77 ◽  
Author(s):  
A. GRÜTERS ◽  
K. SCHNABEL ◽  
D. L' ALLEMAND ◽  
B. WEBER ◽  
H. HELGE

Sign in / Sign up

Export Citation Format

Share Document